Exelixis outlines zanza CRC launch plans as 2026 revenue guidance midpoint is lowered by $50M (NASDAQ:EXEL)

seekingalpha.com · 2026-08-06

Exelixis (EXEL) Q2 2026 earnings call recap: lowered revenue guidance on slower NET ramp, cabo trends, zanzalintinib CRC filing, and catalysts—read now.

Read the full story at seekingalpha.com →